This summary is based on peer-reviewed literature and current clinical guidelines, cited below.
Background
Seasonal allergic rhinitis (AR) affects roughly 1 in 6 Americans and is the most common chronic disease in U.S. children, driving billions of dollars annually in direct costs and lost productivity.1 It results from an IgE-mediated hypersensitivity response: exposure to an aeroallergen (tree, grass, or weed pollen; mold spores) triggers mast cell degranulation and histamine release, producing rhinorrhea, nasal congestion, sneezing, and ocular pruritus. Recognizing the pattern of a patient’s symptoms — and matching it to a rational first-line agent — is one of the highest-value interventions a community pharmacist can offer at the counter.
Clinical Considerations
Oral and Intranasal Antihistamines
Oral second-generation (non-sedating) antihistamines — cetirizine, loratadine, fexofenadine — are recommended over first-generation agents (e.g., diphenhydramine, chlorpheniramine) because they cross the blood-brain barrier minimally, avoiding the sedation and anticholinergic burden associated with older agents.1 The 2015 AAO-HNS clinical practice guideline gives a strong recommendation for oral second-generation antihistamines specifically in patients whose primary complaints are sneezing and itching.1
Intranasal antihistamines (e.g., azelastine) are also an option. In a randomized, double-blind trial comparing intranasal azelastine to intranasal fluticasone propionate in moderate-to-severe seasonal AR, the two classes produced comparable reductions in total nasal and ocular symptom scores, though fluticasone had a modest edge for rhinorrhea specifically.3 This is useful counseling context: intranasal antihistamines are a reasonable alternative for patients who don’t tolerate or don’t respond adequately to an intranasal steroid.
Intranasal Corticosteroids
Intranasal corticosteroids (INCS) — fluticasone, mometasone, budesonide, triamcinolone — are the most effective monotherapy for moderate-to-severe AR and are recommended first-line, particularly when nasal congestion is a dominant symptom.1,2 Onset of meaningful benefit typically takes several hours to days, so counsel patients to use INCS consistently — not just as needed — for best effect. Local adverse effects include nasal irritation and epistaxis; monitor pediatric patients on chronic use for growth-velocity effects.1
Combination therapy (INCS plus an oral or intranasal antihistamine) may be appropriate for patients with an inadequate response to monotherapy, though the evidence for added benefit over INCS alone is mixed depending on the agents compared.2
Decongestants
Oral and intranasal decongestants (pseudoephedrine, oxymetazoline) can provide short-term relief of congestion but are not appropriate for standalone, long-term management. Intranasal decongestants should be limited to 3 days of continuous use to avoid rhinitis medicamentosa (rebound congestion). Pseudoephedrine-containing products remain behind-the-counter under federal law due to methamphetamine-precursor restrictions — an easy counseling opportunity to confirm appropriate use and screen for contraindications such as uncontrolled hypertension.
Allergen Immunotherapy
For patients with an inadequate response to pharmacotherapy plus environmental controls, subcutaneous or sublingual immunotherapy is a guideline-supported option that can modify the underlying allergic response rather than simply treating symptoms.1 Sublingual immunotherapy for pollen allergens is initiated 3–4 months before the anticipated allergy season and is not appropriate for acute symptom relief — a distinction worth reinforcing when patients ask about it mid-season.
Bottom Line for Pharmacists
For most patients with sneezing- and itch-predominant symptoms, a second-generation oral antihistamine is a reasonable first recommendation. When nasal congestion predominates or symptoms are moderate-to-severe, an intranasal corticosteroid used consistently is the better-supported first-line choice. Reserve decongestants for short-term adjunctive use, and refer patients with an inadequate response to appropriate pharmacotherapy for consideration of allergy testing and immunotherapy.
References
- Seidman MD, Gurgel RK, Lin SY, et al. Clinical practice guideline: allergic rhinitis. Otolaryngol Head Neck Surg. 2015;152(1 Suppl):S1-S43. https://doi.org/10.1177/0194599814561600
- May JR, Dolen WK. Management of allergic rhinitis: a review for the community pharmacist. Clin Ther. 2017;39(12):2410-2419. https://doi.org/10.1016/j.clinthera.2017.10.006
- Carr WW, Ratner P, Munzel U, et al. Comparison of intranasal azelastine to intranasal fluticasone propionate for symptom control in moderate-to-severe seasonal allergic rhinitis. Allergy Asthma Proc. 2012;33(6):450-458. https://doi.org/10.2500/aap.2012.33.3626